News articles about Spero Therapeutics (NASDAQ:SPRO) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Spero Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.0552331361989 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- $400,000.00 in Sales Expected for Spero Therapeutics Inc (SPRO) This Quarter (americanbankingnews.com)
- Spero Therapeutics (SPRO) Upgraded by Zacks Investment Research to Hold (americanbankingnews.com)
- Analysts Anticipate Spero Therapeutics Inc (SPRO) Will Announce Earnings of -$1.56 Per Share (americanbankingnews.com)
- Head-To-Head Survey: Aptevo Therapeutics (APVO) versus Spero Therapeutics (SPRO) (americanbankingnews.com)
A number of research firms have recently weighed in on SPRO. Cowen began coverage on Spero Therapeutics in a research note on Monday, November 27th. They issued an “outperform” rating on the stock. Bank of America began coverage on Spero Therapeutics in a research note on Monday, November 27th. They issued a “neutral” rating on the stock. Stifel Nicolaus began coverage on Spero Therapeutics in a research note on Monday, November 27th. They issued a “buy” rating and a $26.00 price target on the stock. Oppenheimer began coverage on Spero Therapeutics in a research note on Monday, November 27th. They issued a “buy” rating and a $30.00 price target on the stock. Finally, ValuEngine raised Spero Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $24.25.
Spero Therapeutics (NASDAQ SPRO) traded up $0.53 on Friday, hitting $10.51. 30,548 shares of the company were exchanged, compared to its average volume of 17,101. Spero Therapeutics has a 1-year low of $9.66 and a 1-year high of $15.40.
Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings data on Thursday, December 14th. The company reported ($36.02) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.43) by ($33.59). The company had revenue of $0.60 million for the quarter, compared to analyst estimates of $0.20 million. research analysts expect that Spero Therapeutics will post -8.52 earnings per share for the current year.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. The Company is developing a portfolio of novel product candidates, including SPR994, Potentiator Platform (SPR741 and SPR206), and SPR720.
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.